Treatment of Migraine Attacks with Subcutaneous Sumatriptan: First Placebo-Controlled Study
- 1 October 1992
- journal article
- clinical trial
- Published by SAGE Publications in Cephalalgia
- Vol. 12 (5), 308-313
- https://doi.org/10.1046/j.1468-2982.1992.1205308.x
Abstract
The results of the very first large-scale placebo-controlled dose-response trial with the novel selective 5-hydroxytryptamine1-like (5HT1-like) receptor agonist sumatriptan are presented. We studied the efficacy and tolerability of subcutaneous injections of 1 mg, 2 mg and 3 mg of sumatriptan in alleviating migraine attacks in a double-blind, placebo-controlled, parallel-group, multicentre clinical trial. Six-hundred and ninety patients were randomized and 685 received study medication. At 30 min, reduction of headache severity to mild or none (primary efficacy endpoint) was achieved in 22% (95% CI: 15-28%) of placebo-treated patients and in 39% (CI: 31-46%) of patients treated with 1 mg sumatriptan, 44% (CI: 36-51%) treated with 2 mg sumatriptan and 55% (CI: 48-63%) treated with 3 mg sumatriptan. Differences from placebo were 17% (CI: 8-27%) for 1 mg sumatriptan, 22% (CI: 13-32%) for 2 mg sumatriptan and 34% (CI: 24-44%) for 3 mg sumatriptan ( p < 0.001 for all three comparisons). Other migraine symptoms were also more effectively treated by sumatriptan than by placebo. Subsequently, an open-label 3 mg dose subcutaneous sumatriptan was given to partial or non-responders. Thirty minutes after this open dose the response rate to sumatriptan had improved to between 70 and 80%. Adverse events after sumatriptan were minor and short-lived. We conclude that subcutaneous sumatriptan is well tolerated in doses up to 3 + 3 mg and may rapidly abort migraine attacks.Keywords
This publication has 14 references indexed in Scilit:
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991
- Epidemiology of headache in a general population—A prevalence studyJournal of Clinical Epidemiology, 1991
- The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura materBritish Journal of Pharmacology, 1990
- Sumatriptan in Acute Migraine: Pharmacology and Review of World ExperienceHeadache: The Journal of Head and Face Pain, 1990
- Early clinical experience with subcutaneous GR43175 in acute migraine: An overviewCephalalgia, 1989
- Serotonin metabolism in migraineNeurology, 1989
- 5-HT1-like receptor agonists and the pathophysiology of migraineTrends in Pharmacological Sciences, 1989
- POSSIBLE BENEFIT OF GR43175, A NOVEL 5-HT1-LIKE RECEPTOR AGONIST, FOR THE ACUTE TREATMENT OF SEVERE MIGRAINEThe Lancet, 1988
- Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster HeadacheClinical Pharmacokinetics, 1985
- NeuroepidemiologyAnnals of Neurology, 1984